ClinicalTrials.gg
Active, not recruitingNCT07113457Updated Nov 19, 2026

Assessing Upper Extremity Function in Chronic Stroke Survivors Through Acute Intermittent Hypoxia

An interventional study of Acute Intermittent Hypoxia (AIH) in Stroke, sponsored by Shirley Ryan AbilityLab. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Stroke by Shirley Ryan AbilityLab — 12 open to participants now, 20 under way, none of them phase 3. Stroke · Shirley Ryan AbilityLab.

Planned enrollment
36th of 55
20 · median 30
Started
2025
with 3 others
No phase
49 of 64
10 open now
Primary completion
2027-08
later than 15 of 19 live
Registered
64th of 64
by date

Among the 64 studies in Stroke by Shirley Ryan AbilityLab, this one is the 36th largest by planned enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 49 with no phase, reaches primary completion later than 15 of the 19 other live ones, and was the 64th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

12 of the 64 studies in Stroke by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Stroke by Shirley Ryan AbilityLab, or all of them as a file.
02

Study summary

Here we aim to observe effects of acute intermittent hypoxia in persons who have experienced a single stroke. We have previously shown this technique to be safe and effective at increasing strength in persons with disabilities, and here are aiming to determine the mechanism of how the breathing method modulates motor function.

Read the detailed description

Here we aim to observe effects of acute intermittent hypoxia in persons who have experienced a single stroke. We have previously shown this technique to be safe and effective at increasing strength in persons with disabilities, and here are aiming to determine the mechanism of how the breathing method modulates motor function.

03

Conditions studied

  • Stroke

Keywords

  • stroke
  • hypoxia
  • spasticity
  • aih
  • ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A first time, unilateral, ischemic, hemispheric stroke, confirmed by MRI
  • Chedoke stage of hand assessment >= 3
  • Ability to open and close affected hand
  • Able to understand and communicate in english
  • Able to independently consent
  • over 6 months post stroke
  • Must have a level above 10g/dl
  • Must have ability to leave research visit with a compainon/group trasportation
  • must be comfortable confirming negative pregnancy prior to hypoxia
  • Must not be involved in any other research intervention study testing upper extremities

Exclusion criteria

Exclusion Criteria:

  • History of prior neurological disorders
  • Brain stem or cerebellar stroke; mean Fazekas score rated on initial fluid-attenuated inversion recovery MRI greater than equal to 3
  • Severe Aphasisa
  • Pre-existing hypoxic pulmonary disease
  • Includes positive Covid-pneumonia diagnosis within 1 year of screening visit
  • Severe hypertension (>160/100)
  • Any ischemic cardiac disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Hypoxia

    Participants in this arm will receive approximately 15 bouts of acute intermittent hypoxia. This intervention involves breathing lowered levels of oxygen (similar to being on a tall mountain) for 60 seconds at a time, followed by 60 seconds of room air. Participants will be assessed following the intervention.

    Other: Acute Intermittent Hypoxia (AIH)

Interventions

  • OtherAcute Intermittent Hypoxia (AIH)

    This intervention involves breathing lowered levels of oxygen (similar to those experienced on a tall mountain) for 60 seconds at a time. This is immediately followed by 60 seconds of breathing normal room air. These bouts are repeated approximately 15 times. For the intervention, the participant is fitted with a non-rebreathing mask which supplies the two different air levels

06

What researchers measure

Primary outcomes

  1. Joint Force Measurement

    The KAIST Upper Limb Synergy Investigation System (KULSIS) will be utilized. KULSIS was developed in collaboration with Neuro- Figure 1: Design of the KULSIS Rehabilitation Engineering Lab at Korea Advanced Institute of Science and Technology, South Korea (Figure 1). It comprises a modular hand and wrist attachment, which connects to a linear actuator. To construct the linear actuator, ball-screw type linear motion module (RS-075N-Z05PR, Robostar, South Korea) was combined with a 100 W AC servo motor (SGM7J-01AFD2C, Yaskawa, Japan). The linear actuator has stroke range of 400 mm, which is ample for adjusting the position of modular hand or wrist attachment to the participant's upper arm before the outcome assessment. Once adjusted, the power of linear actuator will be turned off to fix the position. A six degrees of freedom (DOF) Force/Torque sensor (Series Delta, ATI-Inc. Apex, NC, USA) is positioned between the module and the linear actuator to measure the force and torque applie

    Time frame: 30 minutes following intervention

Secondary outcomes

  1. Stretch reflex measurement:

    Stretch reflex thresholds will be assessed using a custom-designed tendon tapper system (Figure 2.A) based on a Linmot® linear motor (Linmot S.A., Spreitenbach, Switzerland). This system includes a stator and slider with integrated position sensing via a Hall effect sensor, ensuring precise control of tendon indentations and taps. The motor is mounted on a micrometer-driven positioner (Velmex, Bloomfield, NY, USA) for reliable placement of the tapper on the biceps brachii tendon. A multiaxial load cell (Series Nano17, ATI Industrial Automation, Apex, NC, USA) is attached at the tapping end to record applied forces and the resultant reflex responses. Additionally, the tendon tapper integrates a wireless ultrasound device(Figure 2.B) at its tip to provide real-time transverse imaging of the tissue composition surrounding the distal biceps tendon. The ultrasound device features an image resolution of 384 pixels (width) by 400-600 pixels (depth), corresponding to a physical size of 38.4 m

    Time frame: 30 minutes following intervention

  2. Surface EMG measurement

    Surface EMG signals will be recorded using two systems to capture muscle activity during isometric contractions. The Bagnoli-8 EMG system (Delsys Inc, Boston, MA, USA), equipped with standard wired bipolar surface EMG electrodes, will provide localized muscle activity measurements. Additionally, high-density surface EMG (HDsEMG) recordings will be conducted using a 128-channel Refa system (TMSi; Oldenzaal, NL) with an 8×8 electrode grid (8.5 mm inter-electrode distance) to map spatially distributed muscle activity with high resolution (Figure 3). These complementary systems will allow a comprehensive assessment of muscle activation patterns during the study.

    Time frame: 30 minutes following intervention

  3. EKG

    Standard bedside monitoring- a 2-lead tracing to identify dysrhythmias. EKG to be performed throughout hypoxia administration. 12 lead ECG to be performed at visit 1 at resting state with no other ongoing activities

    Time frame: Continuously throughout intervention up to 30 minutes post intervention

  4. Symptom Checklist

    A simple yes/no subjective checklist will be asked and repeated to the subject. Specifically: Chest pain, Shortness of breath, Light headedness, neck pain, dizziness, arm pain, sweaty, sensory changes, increased weakness

    Time frame: at each time point: 2, 6, 14, 24 and 30mins from the beginning of the hypoxia session.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified results will be shared upon request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Within 1 year of study conclusions

Access criteria: Study staff only has access to the full data sets and will provide relevant data upon request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 26 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 8, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Aug 2027was Aug 2026
CompletionEst.
Aug 2028was Aug 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Aug 2027
Nov 19, 2026
Study completion
Aug 2027→Aug 2028
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Aug 2026→Aug 2027
    Study completion Aug 2027→Aug 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07113457
Responsible party
Zev Rymer (Principal Investigator, Shirley Ryan AbilityLab) — Principal investigator
First posted
Aug 8, 2025
Start date
Jun 2, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

William Z Rymer, MD, PhD
principal investigator · Shirley Ryan AbilityLab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion